Research Topics
Genomes and GenesSpecies | Claudio AnasettiSummaryAffiliation: H. Lee Moffitt Cancer Center and Research Institute Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Peripheral-blood stem cells versus bone marrow from unrelated donorsClaudio Anasetti
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
N Engl J Med 367:1487-96. 2012..Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia...
What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?Claudio Anasetti
Department of Blood and Marrow Transplantation, University of South Florida, Moffitt Cancer Center, Tampa, Florida, USA
Best Pract Res Clin Haematol 21:691-7. 2008..Donor CMV serology, parity, and race do not appear to affect outcome. These factors must all be considered in relation to one another when selecting whether to recommend patients for transplant...- Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoidsJoseph Pidala
Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612 USA
Haematologica 96:1351-6. 2011..Advances in acute graft-versus-host disease therapy are needed... - T helper17 cells are sufficient but not necessary to induce acute graft-versus-host diseaseCristina Iclozan
Immunology and Blood and Marrow Transplantation Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33512, USA
Biol Blood Marrow Transplant 16:170-8. 2010..We conclude that Th17 cells are sufficient but not necessary to induce GVHD... - Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaTaiga Nishihori
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Br J Haematol 157:553-63. 2012..Bortezomib combined with high-dose melphalan is a well-tolerated conditioning with some activity in patients with resistant myeloma... - Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomesJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA
Biol Blood Marrow Transplant 17:239-48. 2011..These data suggest an independent adverse effect of dysglycemia in patients treated with glucocorticoids for aGVHD, and argue for stringent glycemic control in this setting... - The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortalityJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612 USA
Haematologica 96:1678-84. 2011..The 2005 National Institutes of Health Consensus Development Conference on chronic graft-versus-host disease proposed major changes in the classification and grading of severity of chronic graft-versus-host disease... - ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantationJoseph Pidala
Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida 33612, USA
Biol Blood Marrow Transplant 17:1237-44. 2011..A regimen of ATG 7.5 mg/kg total ending on day -1 effectively decreased the occurrence of grade III-IV aGVHD and severe chronic GVHD... - Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complicationsJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, FOB 3, Tampa, FL 33612, USA
Int J Hematol 93:206-12. 2011..The addition of rituximab 375 mg/m(2) to t-IV Bu/Flu does not appear to adversely affect engraftment, donor chimerism, or increase the risk of infectious complications... - Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in miceYu Yu
Department of Immunology and Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Blood 118:5011-20. 2011..These data indicate that GVHD can be prevented by targeting Th1 and Th17 transcription factors without offsetting GVL activity... - Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantationJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9416, USA
Biol Blood Marrow Transplant 15:1415-21. 2009..PBSC is the optimal stem cell source in terms of both overall and quality-adjusted life expectancy, except in conditions with a very low relapse probability, in which BM provides optimal outcomes... - A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala
Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, FOB 3308, Tampa, FL 33612, USA
Haematologica 97:1882-9. 2012..Sirolimus-based immune suppression may suppress alloreactive T cells, while sparing the survival and function of regulatory T cells... - CD28 controls differentiation of regulatory T cells from naive CD4 T cellsFei Guo
Immunology and Blood and Marrow Transplantation Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
J Immunol 181:2285-91. 2008..Our study reveals a new aspect of CD28 function in regulating T cell response... - Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effectsYaming Liang
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Blood 111:954-62. 2008..Our data suggest that strategies to target beta2 integrin have clinical potential to alleviate or prevent GVHD while sparing GVL activity... - Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantationJoseph Pidala
Departments of Blood and Marrow Transplantation and Oncological Sciences, University of South Florida, Moffitt Cancer Center, Tampa, FL 33612 9416
Biol Blood Marrow Transplant 15:881-5. 2009..Sirolimus was well tolerated with mild and reversible thrombotic microangiopathy occurring in 2 patients. This experience provides preliminary evidence for the efficacy of sirolimus as a sole primary therapy in the treatment of aGVHD... - Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
J Hematol Oncol 3:36. 2010..However, multivariable analysis did not demonstrate significant differences in overall survival (p = 0.78) or non-relapse mortality (p = 0.6) according to conditioning regimen delivered... - A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxisJanelle Perkins
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Biol Blood Marrow Transplant 16:937-47. 2010..MMF was associated with less early toxicity than MTX but was not as effective in preventing severe aGVHD, especially in unrelated donor transplants... 
Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host diseaseJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Ann Transplant 15:21-9. 2010..We aimed to characterize the activity of pentostatin as rescue therapy for refractory GVHD...- Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Biol Blood Marrow Transplant 17:384-93. 2011..These results support day 90 hypoalbuminemia as an adverse prognostic marker for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome... - Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanismsYu Yu
Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
J Immunol 190:1873-81. 2013..Taken together, these studies demonstrate that both Tc1 and Tc17 cells can mediate effective antitumor immunity through distinct effector mechanisms, but Tc1 cells are superior to Tc17 cells in mediating tumor regression... - Have we improved in preventing and treating acute graft-versus-host disease?Lia Perez
Department of Oncological Sciences, University of South Florida, Florida, USA
Curr Opin Hematol 18:408-13. 2011..Accordingly, progress in the prevention and primary therapy of this complication is needed to improve patient outcomes... - Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signalingKenrick Semple
Department of Pathology and Cell Biology, University of South Florida, Tampa, FL, USA
Blood 117:3096-103. 2011.... - Variation in management of immune suppression after allogeneic hematopoietic cell transplantationJoseph Pidala
Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida 33612, USA
Biol Blood Marrow Transplant 17:1528-36. 2011..These data argue for more rigorous study of IS management post-HCT so that evidence-based practice guidelines can be developed... - Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in miceKenrick Semple
Department of Pathology and Cell Biology, University of South Florida, Tampa, FL 33612, USA
Biol Blood Marrow Transplant 17:309-18. 2011.... - LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in miceDapeng Wang
Departments of Immunology and Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Biol Blood Marrow Transplant 18:1182-1190.e1. 2012..The current study highlights the distinct effects of pan HDACi on allogeneic BMT and alerts that LBH589 (Panobinostat) could have an adverse effect on GVHD, and possibly on other inflammatory diseases... - Stemness of B-cell progenitors in multiple myeloma bone marrowKelly Boucher
Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
Clin Cancer Res 18:6155-68. 2012..In myeloma, B cells and plasma cells show a clonal relationship. Clonotypic B cells may represent a tumor-initiating compartment or cancer stem cell responsible for minimal residual disease in myeloma... - Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectlyAnandharaman Veerapathran
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA
Blood 118:5671-80. 2011.... - Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell deathYu Yu
Departments of Immunology and Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
Blood 114:1026-8. 2009..The resistance of Th17 cells to AICD reveals a novel mechanism to explain the high pathogenicity of Th17 cells in autoimmune diseases, and may also provide a rationale to generate tumor-specific Th17 cells for adoptive immunotherapy... - Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantationJanelle B Perkins
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA
Biol Blood Marrow Transplant 18:1099-107. 2012..Assessment of the higher busulfan AUC on relapse prevention requires trials in patients with a homogeneous risk of relapse... - Glucocorticoid-refractory acute graft-versus-host diseaseJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA
Biol Blood Marrow Transplant 16:1504-18. 2010.... - Quality of life after allogeneic hematopoietic cell transplantationJoseph Pidala
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
Blood 114:7-19. 2009..Behavioral interventions show promise to maintain or improve quality of life after allogeneic HCT. The review concludes with recommendations to investigators and clinicians as the state of this research advances... - Selection of unrelated donors for hematopoietic cell transplantationTeresa Field
Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, The University of South Florida, 12901 Magnolia Dr, Tampa, FL 33612, USA
Curr Hematol Rep 4:270-5. 2005.... - Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomesJanelle B Perkins
Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA
Am J Hematol 87:673-7. 2012..We conclude that while filgrastim/plerixafor is the most efficient remobilization strategy, those clinical benefits may not translate into lower cost, especially when multiple days of plerixafor administration are required... - Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and interventionJoseph Pidala
Department of Blood and Marrow Transplantation, University of South Florida, Tampa, FL, USA
Br J Haematol 148:373-85. 2010..We then discuss evidence in support of the beneficial impact of clinical QOL assessment, and finally evaluate behavioural interventions that show promise to maintain or improve QOL after HCT... - Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?Joseph Pidala
Departmentsof Blood and Marrow Transplantation, Moffitt Cancer Center and Oncological Sciences, University of South Florida, Tampa, FL 33612 9416, USA
Haematologica 95:660-5. 2010.... - Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIPLia Elena Perez
Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
J Immunol 180:1545-55. 2008..In conclusion, the immune cytotoxic effect of Apo2L/TRAIL can be restored at least in part by c-FLIP pathway inhibitors... - Infliximab for managing steroid-refractory acute graft-versus-host diseaseJoseph Pidala
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Biol Blood Marrow Transplant 15:1116-21. 2009..4 for death in those without CR (95% CI=3.6 to 19.6; P < .0001). This series demonstrates the limited activity of infliximab in patients with high-grade aGVHD. Further work is needed to identify effective therapy for aGVHD... - Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving conceptMohamed A Kharfan-Dabaja
Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute and University of South Florida, Tampa, FL 33612, USA
Biol Blood Marrow Transplant 13:373-85. 2007..Treatment of CLL should consider stratification according to modern prognostic markers... - Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remissionJoseph Pidala
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Division of Oncologic Sciences, University of South Florida, Tampa, Florida, USA
Cochrane Database Syst Rev 10:CD008818. 2011.... - To ablate or not to ablate? HSCs in the T cell driver's seatClaudio Anasetti
H Lee Moffitt Comprehensive Cancer Center, Tampa, Florida 33612, USA
J Clin Invest 117:306-10. 2007..We discuss their results in light of the evolving field and their implications for advancing cell-based immunotherapies for cancer... - Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantationJoseph Pidala
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Biol Blood Marrow Transplant 16:729-38. 2010.... - Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus duransMyke R Green
Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
J Oncol Pharm Pract 12:179-81. 2006..We describe an allogeneic bone marrow transplant patient, who was found to have vancomycin-resistant Enterococcus durans bacteremia, which subsequently developed resistance to daptomycin... - Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantationClaudio Anasetti
Blood and Marrow Transplant Program, H Lee Moffitt Cancer Center and Research Institute, Division of Interdisciplinary Oncology, University of South Florida, Tampa, FL, USA
Transplantation 77:S79-83. 2004..Graft-versus-host disease (GVHD) is one of the primary challenges to successful HCT. GVHD, its clinical impact and traditional prophylactic therapies, as well as recent advances in GVHD prevention, are discussed... - Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programsJeffrey R Schriber
Department of Blood and Marrow Transplantation, Banner Health, Phoenix, Arizona, USA
Biol Blood Marrow Transplant 16:595-7. 2010..Expanding much beyond that limit will require an infusion of resources to enlarge current programs and/or establish new programs... - Role and timing of hematopoietic cell transplantation for myelodysplastic syndromeTeresa Field
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, USA
Mediterr J Hematol Infect Dis 2:e2010019. 2010..This review will discuss the role of HCT for MDS based on prognostic features, the optimal timing of HCT, and outcomes based on patient age... - Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myelomaLia E Perez
Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL 33612 9497, USA
Eur J Haematol 84:212-22. 2010..Here, we tested whether bortezomib can reverse the APO2L/TRAIL environmental mediated-immune resistance (EM-IR)... - Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patientsSheri R Jacobs
University of South Florida and H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
J Pain Symptom Manage 33:13-23. 2007..However, the FACT-Cog assesses broader aspects of cognitive complaints, thereby providing greater information about the types of cognitive complaints patients are experiencing... - Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cellsXue Zhong Yu
Immunology and Blood and Marrow Transplantation Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
J Immunol 176:7394-401. 2006..Our findings indicate that ICOS has paradoxical effects on the regulation of alloreactive CD4(+) and CD8(+) T cells in GVHD...
Research Grants
- ANTIGEN SPECIFIC T CELL TOLERANCE BY ANTI CD3 ANTIBODIESClaudio Anasetti; Fiscal Year: 2006..2) Select for low avidity CD3 ligands which induce apoptosis of antigen-activated T cell but no pathogenicity. 3) Define signaling pathways which activate T cell apoptosis in response to CD3 ligation. ..
- ANTIGEN SPECIFIC T CELL TOLERANCE BY ANTI CD3 ANTIBODIESClaudio Anasetti; Fiscal Year: 2009..Showing that non-FcR-binding anti-CD3 mAbs spare T cells specific for viral and tumor-associated antigens is key to predict patient safety. ..
- ANTIGEN SPECIFIC T CELL TOLERANCE BY ANTI CD3 ANTIBODIESClaudio Anasetti; Fiscal Year: 2010..Showing that non-FcR-binding anti-CD3 mAbs spare T cells specific for viral and tumor-associated antigens is key to predict patient safety. ..